News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2019

Epigenomics AG: Results from Microsimulation Model to be presented at renowned health conference

PDF Epigenomics AG: Results from Microsimulation Model to be presented at renowned health conference Berlin (Germany) and San Diego, CA (U.S.A.), October 2, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that Dr. Elvira D’Andrea, MD, MPH, one of the authors of the microsimulation model for comparing outcomes of colorectal cancer screening methods, […]

Read more

Epigenomics AG Highlights Operational Achievements and Reports Financial Results for First Six Months 2019

PDF Berlin (Germany) and San Diego, CA (U.S.A.), August 7, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today announced the operational achievements plus financial results for the second quarter and the first half of 2019. Operational highlights – In January 2019, the Company announced positive results from a microsimulation model for the […]

Read more

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

PDF Berlin, 24 July 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new study results suggesting that Epi proColon®, a CRC screening test approved for patients who are unwilling or unable to be screened by […]

Read more

Chinese Patent Reexamination Department partially invalidates Epigenomics’ patent claims for Septin9

PDF Berlin, 15 July 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announced today that the Reexamination and Invalidation Department of the Patent office, China National Intellectual Property Administration (CNIPA) has, today, deemed Epigenomics’ Septin9 patent in China only partially valid. It has not been recognized for the detection of hepatocellular […]

Read more

Epigenomics AG Receives MedTech Outlook‘s 2019 Top 10 In-Vitro Diagnostics Award

PDF – Company recognized for its leadership in advancing blood-based tests to diagnose cancer Berlin (Germany) and San Diego, CA (U.S.A.), July 11, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 Top 10 In-Vitro Diagnostics Award. Conducted annually, the award […]

Read more

New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

PDF Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary […]

Read more